Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase NA 6Phase 1/2 6Phase 3 4Phase 1 4Phase 2/3 1

Status

Completed 4

Sponsor Class

OTHER 1NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Breast Neoplasms 591Neoplasms 296Carcinoma, Non-Small-Cell Lung 286Prostatic Neoplasms 266Colorectal Neoplasms 213Multiple Myeloma 182Lung Neoplasms 150Neoplasm Metastasis 139Leukemia, Myeloid, Acute 126Leukemia 120Lymphoma 114Lymphoma, Follicular 113Stomach Neoplasms 105Lymphoma, Non-Hodgkin 102Colonic Neoplasms 98Ovarian Neoplasms 96Rectal Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 94Uterine Cervical Neoplasms 93Head and Neck Neoplasms 92Leukemia, Lymphocytic, Chronic, B-Cell 91Pain 90Carcinoma, Hepatocellular 86Pancreatic Neoplasms 81Melanoma 78Lymphoma, Large B-Cell, Diffuse 77Papillomavirus Infections 68Recurrence 66Squamous Cell Carcinoma of Head and Neck 64Parkinson Disease 4, Autosomal Dominant Lewy Body 63

Interventions

Melphalan 3Dexamethasone 3Bortezomib 3daratumumab 1Filgrastim 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Completed × Amyloidosis × Clear all
NCT03201965 2025-11-26

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Janssen Research & Development, LLC

Phase 3 Completed
416 enrolled 28 charts 2 FDA
Plasma cell

Amyloidosis

NCT01078454 2022-02-01

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

National Cancer Institute (NCI)

Phase 3 Completed
11 enrolled 6 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01277016 2017-03-10

EMN-03

European Myeloma Network B.V.

Phase 3 Completed
110 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01998503 2013-11-29

Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis

Nanjing University School of Medicine

Phase 3 Completed
56 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡